VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 41 filers reported holding VERONA PHARMA PLC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,473,589 | -29.7% | 335,803 | -8.9% | 0.00% | – |
Q2 2023 | $7,791,358 | +11.7% | 368,560 | +6.1% | 0.00% | – |
Q1 2023 | $6,972,298 | -22.7% | 347,226 | +0.6% | 0.00% | – |
Q4 2022 | $9,023,343 | – | 345,325 | +2656246.2% | 0.00% | – |
Q3 2022 | $0 | – | 13 | 0.0% | 0.00% | – |
Q2 2022 | $0 | -100.0% | 13 | -100.0% | 0.00% | – |
Q3 2021 | $1,346,000 | -17.7% | 245,594 | -1.7% | 0.00% | – |
Q2 2021 | $1,635,000 | – | 249,941 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |